Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Is it sufficient to evaluate bone marrow involvement in newly diagnosed lymphomas using 18F-FDG PET/CT and/or routine iliac crest biopsy? A new approach of PET/CT-guided targeted bone marrow biopsy

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1Email author
Contributed equally
BMC Cancer201818:1192

https://doi.org/10.1186/s12885-018-5104-0

  • Received: 9 July 2018
  • Accepted: 16 November 2018
  • Published:
Open Peer Review reports

Abstract

Background

To investigate whether PET/CT-guided bone marrow biopsy adds complementary information for evaluation of bone marrow involvement (BMI) in newly diagnosed lymphomas.

Methods

Patients with newly diagnosed lymphomas that received both 18F-FDG PET/CT and bone marrow biopsy (BMB) were included in this retrospective study. PET/CT classification of bone lesions was classified as isolated, multifocal (2 lesions or more), diffuse (homogeneous uptake of the entire axial skeleton), or negative. BMBs included PET/CT-guided targeted BMB and/or the routine unilateral iliac crest biopsy. Of 34 patients with focal lesions on PET/CT scan, 30 received both PET/CT-guided targeted BMB and iliac crest biopsy, and 4 patients received targeted biopsy without iliac crest biopsy. The final diagnosis of BMI depends on BMB results.

Results

A total of 299 patients with lymphomas were included. PET/CT classification of bone lesions was isolated (16/5.4%), multifocal (67/22.4%), diffuse (52/17.4%), and negative (164/54.8%). If only positive iliac crest biopsy was considered as the reference standard, the sensitivity of 18F-FDG PET/CT for identifying focal and diffuse BMI was 48 and 56%, respectively, and the respective specificities were 70 and 83%. Three of 30 patients (10.0%) with focal lesions on PET/CT were confirmed to be false-positive by targeted BMB, and 25 of 30 patients (83.3%) with focal lesions on PET/CT were confirmed as false-negative by iliac crest biopsy.

Conclusion

It is insufficient to evaluate BMI in newly diagnosed lymphomas using both 18F-FDG PET/CT and routine iliac crest biopsy. 18F-FDG PET/CT imaging should be performed before BMB. In focal bone lesions, PET/CT-guided targeted BMB may complement the results of possible false-positive PET/CT and false-negative iliac crest biopsy findings. However, in diffuse and negative lesions, iliac crest biopsy cannot be safely omitted.

Keywords

  • Lymphomas
  • Bone marrow involvement
  • 18F-FDG PET/CT
  • Bone marrow biopsy

Background

Lymphomas are malignant neoplasms characterized by the proliferation of cells native to the lymphoid tissue. In 2015, an estimated 88,200 people will be diagnosed with lymphomas, and there will be approximately 52,100 deaths due to the disease in China [1]. Lymphoma subtype and stage affect therapeutic decisions and prognosis. Thus, accurate assessment of lymphoma patients at initial presentation is necessary for good outcomes.

Bone marrow (BM) is an important extent site, which occurs in 5–15% of Hodgkin lymphomas (HLs), and 20–40% of non-Hodgkin lymphomas (NHLs), depending on the histological subtype [2, 3].The evaluation of BM status is of critical importance in newly diagnosed lymphomas, as it is stage, diagnosis, and if prolonged chemotherapy or radiotherapy may be required.

According to the National Comprehensive Cancer Network (NCCN) guidelines for HL and NHL, routine iliac crest biopsy is essential in all lymphomas where treatment is considered, and is the gold standard for bone marrow staging. Unfortunately, results are subject to sampling error, especially focal bone lesions, which may lead to false-negative iliac crest biopsy results. Previous studies have demonstrate bilateral core biopsies can improves the diagnostic yield, ranging between 10 and 60% [46], however, an additional biopsy means more risk of complications such as bleeding, pain, and anxiety [7, 8].

There is debate about whether 18F-FDG PET/CT scanning can replace routine iliac crest biopsy [913]. The Lugano Classification [14] has noted that 18F-FDG PET/CT is highly sensitive for BMI which may complement the results of routine iliac crest biopsy, and that is has potential for accurate evaluation of BMI in HL and diffuse large B-cell lymphoma (DLBCL). El-Galaly et al. [15] concluded that routine iliac crest biopsy is not required for evaluation of HL if 18F-FDG PET/CT is performed. However, the reference standard according to iliac crest biopsy for true BMI has been questioned [16], since other diseases such as benign conditions or other malignancies can also generate false-positive PET/CT findings [17, 18]. Lim et al. [19] reported that iliac crest biopsy is only needed for DLBCL if the PET/CT finding is negative. The use of PET/CT for evaluation of other subtypes is also controversial. Nevertheless, false-positive PET/CT and false-negative routine iliac crest biopsy results will alter the bone staging of lymphomas. Thus, positive PET/CT findings require histological confirmation, with targeted biopsy preferred to other methods [20, 21].

In our previous study [22], PET/CT-guided targeted BMB was shown to be a safe and effective technique for the evaluation of advanced lung cancer with metastatic bone tumors. However, there are no studies examining the utility of PET/CT-guided targeted BMB, rather than iliac crest biopsy, for bone staging in newly diagnosed lymphomas. The aim of this study was to investigate whether PET/CT-guided targeted BMB adds complementary information for the evaluation of BMI in newly diagnosed lymphomas.

Methods

Patients

We retrospectively reviewed the records of patients with a diagnosis of lymphoma treated at out center from January 2012 to January 2018. Patients were identified through the electronic medical records and pathological reporting systems. Patients were included in this study if 18F-FDG PET/CT-guided targeted BMB or iliac crest biopsy were performed as part of the initial clinical lymphoma staging, and no other malignancy was present.

Patients did not receive chemotherapy prior to 18F-FDG PET/CT scanning, and PET/CT scans were performed within 7 days before or after BMB. Patients were staged according to the Ann Arbor classification. BMI was confirmed based on histological evaluation of biopsy results.

PET/CT technique and imaging

Patients were asked to fast for 4–6 h before 18F-FDG PET/CT scanning. Blood glucose levels were confirmed to be within a maximum value of 120 mg/dL. Intravenous injection of the 18F-FDG tracer was administered at a dosage of 0.1–0.2 mCi/kg. Thereafter, the patient rested for 20 min and was encouraged to drink water. A low-dose CT scan from the head to the proximal femur was performed first, with parameters of 110 kV, 110 mA, a tube rotation time of 0.5 s, and 3.3-mm section thickness, which was matched to the PET section thickness. The second scan was immediately followed by a PET scan of the identical transverse field of view. Emission time was acquired for 3 min per table position.

Data acquisition by an integrated PET/CT system (Discovery STE; GE Medical Systems, Milwaukee, WI, USA) was performed within 60 min of tracer injection. PET/CT image data sets were reconstructed iteratively by applying the CT data for attenuation correction, and co-registered images were displayed on an ADW4.3 or ADW4.6 workstation.

PET/CT images were carefully reviewed by 2 senior nuclear medicine physicians. Most indolent lymphomas demonstrate an increased 18F-FDG uptake, but the degree of 18F-FDG uptake is lower than aggressive lymphomas. If used the positive finding as the uptake over than liver, it may underestimate BMI of indolent lymphomas. 18F-FDG uptake of some indolent lymphomas actually was lower that of liver, especially in diffuse BMI.

Positive PET/CT findings were based on the visual assessment of 18F-FDG uptake in the involved sites relative to that of the mediastinum. PET/CT-assessed bone lesions were characterized as isolated, multifocal, diffuse, and negative. PET/CT-guided targeted BMB was performed to determinate the diagnosis and bone staging of lymphomas.

BMB

Two methods of BMB were performed: 1) routine unilateral iliac crest biopsy and 2) PET/CT-guided targeted bone marrow biopsy.

Unilateral iliac crest BMB was routinely in newly diagnosed lymphoma patients performed before any treatment was administered. One sample was obtained for each patient, and lengths of the samples were 1.0 cm.

PET/CT-guided targeted BMB was performed by 1 board certified nuclear medicine physician using the same PET/CT scanner on a separate day to reduce the radiation dose to the operator.18F-FDG PET/CT fused images were used to determine the appropriate puncture site with high FDG uptake, and the biopsy needle was introduced stepwise under fused PET/CT image and CT guidance. An 11G (BMN-B, SA Medical & Plastic Instruments Co., Ltd., Shanghai, China) biopsy needle was used. One or two samples were obtained for each patient, and the lengths of samples all were 1.5 or 2.2 cm.

All patients were kept for observation for at least 2 h after the biopsy procedure. The BMB specimens were analyzed by morphological and immunohistochemical studies. The pathological results of all BMBs were validated by review of the individual pathology reports.

Reference standard

Three reference standards for true BMI were used: 1) the iliac crest biopsy; 2) both focal skeletal PET/CT lesions and positive iliac crest biopsy; 3) PET/CT-guided targeted BMB.

Statistical analysis and ethics

Median and range were reported for continuous variables, and counts and percentages for categorical variables. Clopper-Pearson exact confidence limits were calculated for sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. Differences between PET/CT-guided targeted BMB and routine BMB were analyzed using Fisher exact test. All statistical analysis was performed using SPSS, version 23, and MedCalc, version 12.2.1 software. The P value for statistical significance was set to P < .05. This retrospective evaluation of collected data was approved by the ethics committee of our institution. All patients gave their written informed consent prior to any procedures performed.

Results

Inclusion criteria

A total of 317 patients with lymphomas were identified and screened for eligibility. Twelve patients did not have an iliac crest biopsy in the staging workup, and 6 patients had another coexisting malignancy, and were thus excluded. Thus, 299 patients met the inclusion criteria and were included in the analysis. Of 299 patients identified, 295 patients received an iliac crest biopsy, and 4 patients had only a targeted biopsy. Of the 295 patients received an iliac crest biopsy, 30 patients with focal lesions received both a targeted biopsy and the iliac crest biopsy. Most of the suspicious lymphoma patients will be recommended for PET/CT examination to further diagnosis and differential diagnosis. It is difficult to get definite lymphomas subtypes diagnosis before PET/CT examination in daily clinical practice.

Study flow diagram is shown in Fig. 1.
Fig. 1
Fig. 1

Study flow diagram

Clinicopathological characteristics

The median age of patients in the study was 54.8 years (range, 4–91 years), and the male: female ratio was 1:5. The lymphoma subtypes were classified as HL, low-grade, high-grade, NHL, unclassification, Richter transformation and others. Patient characteristic are summarized in the Table 1.
Table 1

Clinicopathologic Characteristics of the Study Cohort (n = 299)

Characteristic

No. of patients

%

Study subject

299

Male: Female ratio

1.5

Age, years

 median

54.8

 range

4–91

PET-assessed skeletal pattern

 Focal, isolated

16

5.4

 Focal, multiple

67

22.4

 Diffuse

52

17.4

 Negative

164

54.8

Subtypes of lymphoma

 Hodgkin lymphomaa

25

8.4

 Low-grade Non-Hodgkin lymphomab

68

22.7

 High-grade Non-Hodgkin lymphomac

170

56.9

 Unclassificationd

17

5.7

 Richter transformation

5

1.7

 Others

14

4.6

Abbreviations: NLP Nodular lymphocyte predominant, NS Nodular sclerosis lymphomas, MC Mixed cellularity, LR Lymphocyte-rich, DLBC Diffuse large B cell, PTC Peripheral T cell, BL Burkitt lymphoma, ACL Anaplastic large cell, MZ Marginal zone, MC Mantle cell, MALT Mucosa-associated lymphoid tissue, SLL/CLL Chronic lymphocytic leukemia/small lymphocytic lymphoma

aHodgkin lymphoma included 3 NLP, 10 NS, 8 MC, 4 LR

bLow-grade Non-Hodgkin lymphoma included 24 Follicular,10 MZ, 13 MC, 9 MALT, 12 SLL/CLL

cHigh-grade Non-Hodgkin lymphoma included 129 DLBC, 8 PTC, 2 BL, 5 ACL, 2 Lymphoblastic, 25 NK-T

dUnclassification included 8 B-cell lymphomas, 8 T-cell lymphomas

PET/CT classification of bone lesions in newly diagnosed lymphomas

Abnormal skeletal FDG uptake was present in 135 patients (45.2%). Eighty-three of 135 had focal lesions (isolated, 16; multifocal, 67). Of the 83 patients, 16 had positive iliac crest biopsies; 52 of 135 had diffusely homogeneous FDG uptake. Of the 52 patients, 22 had positive iliac crest biopsies involving most of the axial skeleton. Negative skeletal FDG uptake was present in 164 patients (54.8%), of whom 17 had positive iliac crest biopsies. PET/CT data are summarized in Table 2.
Table 2

Concordance Between Bone Marrow Biopsy and PET/CT Findings for Evaluation of Bone Marrow Disease (n = 295)

 

Bone marrow involvement

Total

+

PET focal bone lesions

16

63

79

PET diffuse bone lesions

22

30

52

PET negative

17

147

164

Total

55

240

295

Diagnostic performance of 18F-FDG PET/CT and iliac crest biopsy for determination of BMI

Results of the diagnostic performance of 18F-FDG PET/CT and iliac crest biopsy for evaluating BMI are shown in Table 3. If only positive iliac crest biopsy was considered the reference standard for true BMI, the sensitivity and specificity of 18F-FDG PET/CT for detection of focal bone lesions were 48% (95% confidence interval [CI]: 31 to 66%) and 70% (95% CI: 63 to 76%), respectively. The PPV and NPV were 20% (95% CI: 12 to 31%) and 90% (95% CI: 84 to 94%), respectively. The overall diagnostic accuracy (the proportion of true-positive and true-negative results over the total number of tests performed) was 67% (95% CI: 61 to 73%). For diffuse lesions, the sensitivity and specificity were 56% (95% CI: 40 to 72%) and 83% (95% CI: 77 to 88%), respectively. The PPV and NPV were 42% (95% CI: 30 to 57%) and 90% (95% CI: 84 to 90%), respectively. The overall diagnostic accuracy was 78% (95% CI: 72 to 83%).
Table 3

Sensitivity, Specificity, PPV, NPV, and Accuracy of the Iliac Crest Biopsy and PET/CT for Detection of Bone Marrow Disease in the 295 patients

Diagnostic Modality

%

95%CI

 

%

95%CI

 

Bone Disease Defined Only by Positive Iliac crest biopsy (n = 55)

Iliac crest biopsy

 Focal

  

Diffuse

  

  Sensitivity

N/Aa

 

Sensitivity

N/Aa

 

  Specificity

N/Aa

 

Specificity

N/Aa

 

  PPV

N/Aa

 

PPV

N/Aa

 

  NPV

N/Aa

 

NPV

N/Aa

 

  Accuracy

N/Aa

 

Accuracy

N/Aa

 

PET/CT

 Focal

  

Diffuse

  

  Sensitivity

48

31 to 66

Sensitivity

56

40 to 72

  Specificity

70

63 to 76

Specificity

83

77 to 88

  PPV

20

12 to 31

PPV

42

30 to 57

  NPV

90

84 to 94

NPV

90

84 to 90

  Accuracy

67

61 to 73

Accuracy

78

72 to 83

 

Bone Disease Defined Only by Positive Iliac crest biopsy and/or FDG-avid bone lesion (n = 148)

Iliac crest biopsy

 Focal

  

Diffuse

  

  Sensitivity

34

25 to 45

Sensitivity

57

44 to 68

  Specificity

N/Ab

 

Specificity

N/Ab

 

  PPV

N/Ab

 

PPV

N/Ab

 

  NPV

70

63 to 76

NPV

83

77 to 88

  Accuracy

74

68 to 79

Accuracy

86

81 to 90

PET/CT

 Focal

  

Diffuse

  

  Sensitivity

82

71 to 88

Sensitivity

75

63 to 85

  Specificity

N/Ab

 

Specificity

N/Ab

 

  PPV

N/Ab

 

PPV

N/Ab

 

  NPV

90

84 to 94

NPV

90

84 to 94

  Accuracy

93

89 to 96

Accuracy

92

88 to 95

Abbreviations: PET Positron emission tomography, CT Computed tomography, N/A Not applicable, NPV Negative predictive value, PPV Positive predictive value

P < 0.05 for difference between the routine iliac crest biopsy and PET/CT for detection of bone marrow disease

aN/A because iliac crest biopsy is considered the gold standard in this analysis

bN/A because of missing reference for true positive

If focal skeletal PET/CT lesions and positive iliac crest biopsy were both considered as the reference standard for true BMI, the sensitivity of focal bone lesions was 82% (95% CI: 71 to 88%) for PET/CT versus 34% (95% CI: 25 to 45%) for iliac crest biopsy. The NPVs were 90% (95% CI: 84 to 94%) for PET/CT versus 70% (95% CI: 63 to 76%) for iliac crest biopsy. The overall diagnostic accuracy was 93% (95% CI: 89 to 96%) for PET/CT versus 74% (95% CI: 68 to 79%) for iliac crest biopsy. As for diffuse lesions, the sensitivity was 75% (95% CI: 63 to 85%) for PET/CT versus 57% (95% CI: 44 to 68%) for iliac crest biopsy. The NPVs were 90% (95% CI: 84 to 94%) for PET/CT versus 83% (95% CI: 77 to 88%) for iliac crest biopsy. The overall diagnostic accuracy was 92% (95% CI: 89 to 95%) for PET/CT versus 86% (95% CI: 81 to 90%) for iliac crest biopsy.

PET/CT findings of indolent lymphomas

The main subtypes of indolent lymphomas were follicular, marginal zone, mucosa-associated lymphoid tissue (MALT), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) and mantle cell lymphomas. The 18F-FDG avidity of this group of lymphomas was demonstrated in Table 4.
Table 4

18F-FDG avidity of Indolent lymphomas

Indolent lymphomas subtype

N

18F-FDG-avid

Negative

%18F-FDG-avid

Focal/Diffuse/Negative bone lesions

Follicular

24

20

4

83.3

2/4/18

Marginal zone

10

9

1

90

1/6/3

MALT

9

6

3

66.7

0/0/9

SLL/CLL

12

9

3

75

2/4/6

Mantle cell

13

13

0

100

0/3/10

Abbreviations: MALT Mucosa-associated lymphoid tissue, SLL/CLL Small lymphocytic lymphoma/chronic lymphocytic leukemia

Differences of bone staging between PET/CT-guided targeted BMB and iliac crest biopsy for focal bone lesions

A comparison of the diagnostic performance between PET/CT-guided targeted BMB and iliac crest biopsy for the assessment of focal BM disease in the 30 patients is shown in Table 5. The diagnostic ability of targeted BMB was superior to that of iliac crest biopsy (sensitivity of 90.0% versus 16.7%, respectively, P < 0.05). Three of 30 patients with a negative targeted biopsy were confirmed to have false-positive PET/CT findings, and the pathological results included 1 eosinophilic granuloma with fibrosis, 1 myelodysplastic syndrome (MDS), and 1 active bone marrow hyperplasia. Twenty-five of 30 patients with focal lesions on PET/CT scan were confirmed to have false-negative results of iliac crest biopsies. In addition, in 4 patients who had a targeted BMB without an iliac crest biopsy, the diagnosis and bone staging was established in a single procedure.
Table 5

A Comparison of the Diagnostic Performance Between PET/CT-guided Targeted BMB and Iliac Crest Biopsy for the Assessment of Focal Bone marrow disease on PET/CT scan in the 30 patients

 

Pathological results

Total

P

+

Target bone biopsy(n = 30)

27 (90.0%)

3a (10.0%)

30

< 0.05

Routine iliac crest biopsy(n = 30)

5 (16.7%)

25 (83.3%)

30

aNegative results include one Eosinophilic granuloma with fibrosis, one myelodysplastic syndrome (MDS) and one active bone marrow hyperplasia

Fisher exact test

BMB related inflammatory response and complications

Forty-eight patients with focal lesions received PET/CT scan after BMB. In those patients, only 4(8.3%) patients had slightly 18F-FDG uptake in the puncture site, the degree of 18F-FDG uptake of puncture site is obviously lower than that of lesions of BMI. The average time to perform a biopsy was 30 min. Slight bleeding and pain occurred in almost all patients who underwent a biopsy, but no serious complications were noted (Table 6).
Table 6

Analysis of the 34 PET/CT-guided targeted BMBs for PET-assessed staging IV patients

Biopsy site

No. of biopsies

Biopsy procedure

Diagnosis

Bone morpholovic abnormalities on CT findings

Success

Complications

Subtypea

Otherb

No. of Yes

No. of No

Slight pain

Slight bleeding

Ilium

22

22

15

15

19

3

15

8

Sacrum

6

6

5

4

6

0

1

5

Ischium

3

3

3

3

3

0

1

1

Rib

1

1

0

0

1

0

1

0

Femur

2

2

2

2

2

0

1

1

Total

34

34

25

24

31

3

19

15

aSubtype means definite subtype diagnosis, such as diffuse large B cell lymphoma

bOther include one Eosinophilic granuloma with fibrosis, one myelodysplastic syndrome (MDS) and one active bone marrow hyperplasia

Representative images are shown in Figs. 2, 3, 4, 5 and 6.
Fig. 2
Fig. 2

PET/CT classification of bone marrow involvement (maximum intensity projection images, MIP). a Isolated lesion in the left ilium (black arrow). b Multifocal lesions in bone marrow. c Diffuse lesions in axial skeleton. d Negative PET findings in bone marrow

Fig. 3
Fig. 3

PET/CT-guided targeted bone marrow biopsy procedure. a-c 18F-FDG PET/CT findings. a The MIP image showed multifocal lesions in the region of bone and abdomen. b and c Axial CT image, axial PET/CT fusion image, showed high 18F-FDG uptake within the left ilium (white arrow), while no overt bony change was observed within the corresponding hypermetabolic region. d Procedure of biopsy target selection. e Puncture process using a 16G bone biopsy needle. f CT image showed the biopsy needle positioned within the left ilium lesion (white arrow). g Histological examination combined with immunohistochemical result confirmed a diagnosis of NHL (high-grade B cell lymphoma), suggesting further examination with C-MYC, Bcl-2, and Bcl-6 genetic testing

Fig. 4
Fig. 4

A patient with mixed cell Hodgkin lymphoma, who was suspected of having multifocal bone lesions on the PET/CT image. Targeted biopsy confirmed false-positive PET findings. a MIP image showed multifocal bone lesions. b and c Axial CT image, axial PET/CT fusion image, showed high 18F-FDG uptake within the right ilium (white arrow) and osteolytic destruction was observed within the corresponding hypermetabolic region (white arrow). d CT image showed the biopsy needle positioned within the right ilium lesion (arrow). e Histological examination combined with immunohistochemical result confirmed the diagnosis of eosinophilic granuloma with fibrosis

Fig. 5
Fig. 5

A patient who was suspected of having a lymphoma based on 18F-FDGPET/CT findings. Both diagnosis and staging were completed through PET/CT-guided targeted bone marrow biopsy in one procedure. The iliac crest biopsy was negative. a MIP image showed high 18F-FDG uptake within lesions in multiple retroperitoneal lymph nodes, spleen, and isolated left ilium. b and c PET/CT image showed high 18F-FDG uptake (SUVmax 3.38) within the left ilium, while no abnormality was observed on corresponding CT image (arrow). d CT image showed the biopsy needle positioned within the left ilium lesion (arrow). e Histological examination combined with immunohistochemical result confirmed a diagnosis of DLBCL

Fig. 6
Fig. 6

A patient with suspected lymphoma involvement in multiple areas of bone marrow, liver, spleen, and lymph nodes. She received targeted biopsy for diagnosis and staging. a MIP image showed high 18F-FDG uptake within lesions in the bone marrow, liver, spleen, and lymph nodes. b and c Axial PET/CT image showed high 18F-FDG uptake (SUVmax 17.34) within the left ilium, and abnormality on the corresponding CT image (arrow). d CT image showed the biopsy needle positioned within the left ilium lesion (arrow). e Histological examination combined with immunohistochemical result confirmed a diagnosis of DLBCL. f MIP of follow-up 18F-FDG PET/CT at the end of chemotherapy showed no hypermetabolic lesions (complete response)

Discussion

To our knowledge, this study is the first to propose the notion that PET/CT-guided targeted BMB can add pathological confirmation of focal BMI in newly diagnosed lymphomas. Based on the data that 18F-FDG PET/CT overcomes deficiencies of iliac crest biopsy, targeted BMB has gradually become routine practice at our institution.

18F-FDG PET/CT has been widely accepted for the evaluation of focal BMI of HL, without the need for routine iliac crest biopsy [14, 15]. However, its actual diagnostic value is difficult to determine because of scarce target biopsies, and only the iliac crest biopsy as a reference standard for true BMI may erroneously generate false-positive PET/CT and false-negative iliac crest biopsy results. Our results demonstrated that 1 of 2 patients with HL with focal bone lesions on PET/CT scan, together with a negative iliac crest biopsy, confirmed the false-positive PET/CT findings via a targeted biopsy. If all subtypes were included, in the 30 patients in whom a targeted biopsy and an iliac crest biopsy were performed, 3 of 30 patients who had a positive PET/CT findings were shown to have other BM diseases rather than lymphoma BMI by targeted biopsy. Therefore, although 18F-FDG PET/CT can easily detect the bone lesions, positive findings also required histological examination, even in cases of HL.

Adequate imaging is a prerequisite for performing a biopsy to establish a diagnosis. Advances in imaging techniques have contributed to the increasing use of image-guided percutaneous biopsy for the diagnosis of primary and secondary bone tumors [23, 24].18F-FDG PET/CT is the preferred method for determining the choice of biopsy site, as it is superior to other imaging methods [25]. Compared to a conventional CT-guided biopsy, the dual modality technique provides co-registered information about both the morphology and physiology of the proposed biopsy site, and can offer a target that exhibits increased FDG uptake [26]. In addition, whole body PET/CT allows visualization of the entire marrow and provides better visualization of poorly defined bone abnormalities than other modalities [27, 28]. In our study, 19 of 34 patients had no bone abnormalities on CT and were thus not suitable for CT-guided biopsy, while PET/CT identified an accurate biopsy site. Most importantly, the PET/CT classification of bone lesions of lymphomas is useful for determining the choice of biopsy. The pattern of skeletal FDG uptake was categorized as isolated, multifocal, diffuse, and negative. Our results also demonstrated 5 of 68 patients (7.4%) with focal 18F-FDG–avid bone lesions in indolent lymphomas. Individual algorithms for evaluation of BMI should be performed for various bone lesions identified on PET/CT imaging. In general, failure to follow appropriate biopsy procedures may lead to inaccurate bone staging.

Currently, routine iliac crest biopsy is still the standard bone staging method for patients with newly diagnosed lymphomas [29]. However, it is well-known that the procedure is associated with low sensitivity in newly diagnosed lymphomas, especially those with focal BMI. In other words, a negative routine iliac crest biopsy cannot rule out the presence of BMI. Our results showed that PET/CT had a sensitivity of 48% in 79 patients with focal bone lesions. Sampling error, especially outside the iliac crest, may be major factor. Thus, it is preferable to use PET/CT-guided targeted BMB in the case of positive PET/CT findings to easily obtain representative tissue. First, a separate staging procedure adds time, cost, coordination of care, inconvenience, and an additional anesthetic risk [7, 30].In the 34 patients in our study,4 patients were simultaneously confirmed diagnosis and stage of lymphoma only through targeted BMB so that iliac crest biopsy could be avoided. Second, targeted biopsy avoided false-positive PET/CT findings in 3 of 34 patients in our study, which can result in inaccurate staging. Third, targeted biopsy was obviously superior to routine iliac crest biopsy in our study (sensitivity of 90.0% for targeted biopsy vs. 16.7% for iliac crest biopsy), and a false-negative iliac crest biopsy was avoided. In addition, we believe that targeted biopsy is a suitable reference standard to calculate the specificity of bone marrow 18F-FDG PET.

PET/CT-guided targeted BMB is a safe and feasible method for bone lesions [27, 3133]. The preferred choice of puncture site for an individual patient depends on the size and location and local experience and expertise. In our study, the relatively safer puncture site that is suspicious BMI on 18F-FDG PET/CT was preferred consideration and no serious complications were noted. Meanwhile, an adequate amount of tissue is required for immunophenotyping and genetic testing to establish a definitive diagnosis of lymphomas [29]. In our study, an adequate amount of tissue was obtained in all 34 patients and definitive subtype diagnosis was determined in 31 of 34 patients. The overall success rate was 91.2%. The remaining two patients were diagnosed with B-cell lymphomas, and didn’t receive immunophenotyping and genetic testing for differential diagnosis due to lack of funds. Thus, our biopsy procedure actually showed a safe, feasible and effective method for diagnosis of lymphomas. When an FDG-avid peripheral lymph node is not present, or in the case of primary bone lymphoma, a targeted BMB is a potential alternative for accurate diagnosis, and complete staging in a single procedure. However, targeted bone marrow biopsy in some localizations may be relatively difficult, such as skull, anterior part of vertebra .etc. The puncture site should be selected in the relatively safe localizations for advoiding serious complication.

Diffuse bone lesions on PET/CT scan are usually defined as homogeneous increased FDG uptake of the entire axial skeleton, and are a well-known phenomenon in patients treated with hematopoietic growth factors [34, 35]. However, the finding is relatively uncommon in newly diagnosed lymphomas [36]. In a study by Admas et al. [37], the incidence of diffuse bone lesions on PET/CT scan was 4.2% (23/542), and the frequency of positive iliac crest biopsies was 55.0% (11/20) in newly diagnosed lymphomas. But our current study reported that the incidences of diffuse skeletal uptake were about 17.4%. The difference in the incidences is due to the different PET positive standard. We considered 18F-FDG FDG uptake greater the mediastinum as PET positive standard, while Hugo J.A. Adams refer to 18F-FDG FDG uptake greater than liver. Thus, it is explainable why the incidence of diffuse bone marrow FDG uptake in our current study was higher than that of Hugo J.A. Adams,s results. This present study showed that 18F-FDG PET/CT does not exhibit very good concordance with the results of iliac crest biopsy, and its sensitivity and specificity were only 56 and 83%, respectively. Thus, iliac crest biopsy is more useful for diffuse bone lesions seen on PET/CT scan compared with other modality.

A routine iliac crest biopsy also cannot be safely omitted in the case of negative bone marrow PET/CT findings, except in cases of DLBCL [14, 19].In our study, we did not find positive iliac crest biopsy results if the PET/CT was negative in patients with DLBCL. But in other subtypes of lymphomas, of 164 patients who had negative PET/CT results, 17 had positive iliac crest results, resulting in an overall NPV of 90%. Thus, 10% of the patients would be inaccurate staging if the iliac crest biopsy was not performed.

Some limitations of this study should be acknowledged. First, the sample size of PET/CT-guided targeted BMBs was limited. We tried to retrieve multi-center date to test and verify our results. Second, only 18F-FDG PET/CT and iliac crest biopsy were studied, more other modality, such as MRI, laboratory examination, etc. must be considered. Finally, subtypes of lymphomas present differences depending on various PET/CT findings. In regard to these problems, more studies will be followed in the future gradually.

Conclusion

It is insufficient to evaluate BMI in newly diagnosed lymphomas using both 18F-FDG PET/CT and routine iliac crest biopsy. It is recommended that 18F-FDG PET/CT imaging be performed before any BMB. In focal lesions identified on 18F-FDG PET/CT scan, it is preferable to PET/CT-guided targeted biopsy, because it could not exclude possible false-positive PET/CT findings, even in HL, and can also avoid additional blind biopsies. However, in diffuse and negative lesions identified on 18F-FDG PET/CT scan, iliac crest biopsy cannot be safely omitted.

Notes

Abbreviations

95%CI: 

95% confidence interval

BM: 

Bone marrow

BMI: 

Bone marrow involvement

DLBCL: 

Diffuse large B-cell lymphoma

HL: 

Hodgkin lymphoma

MALT: 

Mucosa-associated lymphoid tissue

MDS: 

Myelodysplastic syndrome

NCCN: 

National Comprehensive Cancer Network

NHL: 

Non-Hodgkin lymphomas

NPV: 

Negative predictive value

PPV: 

Positive predictive value

SLL/CLL: 

Small lymphocytic lymphoma/chronic lymphocytic leukemia

Declarations

Acknowledgements

We are indebted to Nuclear department & Minnan PET Center of Fujian Province for providing technical assistance. We also thank all the patients for allowing us to analyze their data.

Funding

This study was funded by the National Natural Science Foundation of China (81101067), the Natural Science Foundation of Fujian Province of China (2015 J01543) and the second batch of science and technology projects in Xiamen (3502Z20164011). Funding bodies were not involved in the design of the study, collection, analysis, and interpretation of date or in writing the manuscript.

Availability of data and materials

The datasets and materials used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

BH, LZ, LS carried out conception and design. BH, LZ, WG, NL, HF, YP, HC, JW carried out collection and assembly of data. BH, LZ, XG, DR and ZL carried out data analysis and interpretation. JW, DR and XG carried out PET/CT acquisition and collection of clinical data. HW, LS and LZ provided critical comments for this manuscript. BH, LZ, YP, HW and LS participated in manuscript writing and revision. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Xiamen University, Xiamen, China (KYX-2012 012). Written informed consent was obtained from each participant.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Rd, Xiamen, 361003, Fujian, China

References

  1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.View ArticleGoogle Scholar
  2. Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin’s lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska lymphoma study group. J Clin Oncol. 1990;8(7):1163–72.View ArticleGoogle Scholar
  3. Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V. Bone marrow involvement in Hodgkin’s disease: an analysis of 135 consecutive cases. German Hodgkin’s lymphoma study group. J Clin Oncol. 1995;13(2):403–9.View ArticleGoogle Scholar
  4. Brunning RD, Bloomfield CD, McKenna RW, Peterson LA. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med. 1975;82(3):365–6.View ArticleGoogle Scholar
  5. Juneja SK, Wolf MM, Cooper IA. Value of bilateral bone marrow biopsy specimens in non-Hodgkin’s lymphoma. J Clin Pathol. 1990;43(8):630–2.View ArticleGoogle Scholar
  6. Wang J, Weiss LM, Chang KL, Slovak ML, Gaal K, Forman SJ, Arber DA. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer. 2002;94(5):1522–31.View ArticleGoogle Scholar
  7. Brunetti GA, Tendas A, Meloni E, Mancini D, Maggiore P, Scaramucci L, Giovannini M, Niscola P, Cartoni C, Alimena G. Pain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignancies. Ann Hematol. 2011;90(10):1233–5.View ArticleGoogle Scholar
  8. Bain BJ. Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004. Haematologica. 2006;91(9):1293–4.PubMedGoogle Scholar
  9. Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, van der Walt J, Timothy AR. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91(9):3340–6.PubMedGoogle Scholar
  10. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16(2):603–9.View ArticleGoogle Scholar
  11. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46(6):958–63.PubMedGoogle Scholar
  12. Cetin G, Cikrikcioglu MA, Ozkan T, Karatoprak C, Ar MC, Eskazan AE, Ayer M, Cerit A, Gozubenli K, Uysal BB, et al. Can positron emission tomography and computed tomography be a substitute for bone marrow biopsy in detection of bone marrow involvement in patients with Hodgkin’s or non-Hodgkin’s lymphoma? Turk J Haematol. 2015;32(3):213–9.PubMedPubMed CentralGoogle Scholar
  13. Pelosi E, Penna D, Douroukas A, Bello M, Amati A, Arena V, Passera R, Bisi G. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging. 2011;55(4):469–75.PubMedGoogle Scholar
  14. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.View ArticleGoogle Scholar
  15. El-Galaly TC, d'Amore F, Mylam KJ, de Nully Brown P, Bogsted M, Bukh A, Specht L, Loft A, Iyer V, Hjorthaug K, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30(36):4508–14.View ArticleGoogle Scholar
  16. Adams HJ, Kwee TC, Nievelstein RA. Influence of imperfect reference standard bias on the diagnostic performance of MRI in the detection of lymphomatous bone marrow involvement. Clin Radiol. 2013;68(7):750–1.View ArticleGoogle Scholar
  17. Inoue K, Goto R, Okada K, Kinomura S, Fukuda H. A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity. Ann Nucl Med. 2009;23(7):643–9.View ArticleGoogle Scholar
  18. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N, Sato N, Inoue T, Endo K. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 2001;219(3):774–7.View ArticleGoogle Scholar
  19. Lim ST, Tao M, Cheung YB, Rajan S, Mann B. Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy? Ann Oncol. 2005;16(2):215–8.View ArticleGoogle Scholar
  20. Welker JA, Henshaw RM, Jelinek J, Shmookler BM, Malawer MM. The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses. Cancer. 2000;89(12):2677–86.View ArticleGoogle Scholar
  21. Mitsuyoshi G, Naito N, Kawai A, Kunisada T, Yoshida A, Yanai H, Dendo S, Yoshino T, Kanazawa S, Ozaki T. Accurate diagnosis of musculoskeletal lesions by core needle biopsy. J Surg Oncol. 2006;94(1):21–7.View ArticleGoogle Scholar
  22. Guo W, Hao B, Chen HJ, Zhao L, Luo ZM, Wu H, Sun L. PET/CT-guided percutaneous biopsy of FDG-avid metastatic bone lesions in patients with advanced lung cancer: a safe and effective technique. Eur J Nucl Med Mol Imaging. 2017;44(1):25–32.View ArticleGoogle Scholar
  23. Gogna A, Peh WC, Munk PL. Image-guided musculoskeletal biopsy. Radiol Clin N Am. 2008;46(3):455–473, v.View ArticleGoogle Scholar
  24. Wu Y, Su LP, Yang XT, Zhang JX, Zhao M, Zhang Z, Guan T, Liu XL, Zheng YP, Han WE. Preliminary evaluation of PET-CT and DWI for the detection of lymphoma bone marrow infiltration. Zhonghua Zhong Liu Za Zhi. 2016;38(11):853–60.PubMedGoogle Scholar
  25. Chowdhury FU, Shah N, Scarsbrook AF, Bradley KM. [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. Postgrad Med J. 2010;86(1013):174–82.View ArticleGoogle Scholar
  26. Hao B, Guo W, Luo NN, Fu H, Chen HJ, Zhao L, Wu H, Sun L. Metabolic imaging for guidance of curative treatment of isolated pelvic implantation metastasis after resection of spontaneously ruptured hepatocellular carcinoma: a case report. World J Gastroenterol. 2016;22(41):9242–6.View ArticleGoogle Scholar
  27. Cornelis F, Silk M, Schoder H, Takaki H, Durack JC, Erinjeri JP, Sofocleous CT, Siegelbaum RH, Maybody M, Solomon SB. Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities. Eur J Nucl Med Mol Imaging. 2014;41(12):2265–72.View ArticleGoogle Scholar
  28. Klaeser B, Wiskirchen J, Wartenberg J, Weitzel T, Schmid RA, Mueller MD, Krause T. PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact. Eur J Nucl Med Mol Imaging. 2010;37(11):2027–36.View ArticleGoogle Scholar
  29. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, et al. NCCN guidelines insights: non-Hodgkin’s lymphomas, version 3.2016. J Natl Compr Canc Netw. 2016;14(9):1067–79.View ArticleGoogle Scholar
  30. Adams HJ, Nievelstein RA, Kwee TC. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. Blood Rev. 2015;29(6):417–25.View ArticleGoogle Scholar
  31. Matti A, Farolfi A, Frisoni T, Fanti S, Nanni C. FDG-PET/CT guided biopsy in Angiosarcoma of bone: diagnosis, staging and beyond. Clin Nucl Med. 2018;43(2):e48–9.PubMedGoogle Scholar
  32. Adams HJ, de Klerk JM, Heggelman BG, Dubois SV, Kwee TC. Malignancy rate of biopsied suspicious bone lesions identified on FDG PET/CT. Eur J Nucl Med Mol Imaging. 2016;43(7):1231–8.View ArticleGoogle Scholar
  33. Maciel MJ, Tyng CJ, Barbosa PN, Bitencourt AG, Matushita Junior JP, Zurstrassen CE, Chung WT, Chojniak R. Computed tomography-guided percutaneous biopsy of bone lesions: rate of diagnostic success and complications. Radiol Bras. 2014;47(5):269–74.View ArticleGoogle Scholar
  34. Knopp MV, Bischoff H, Rimac A, Oberdorfer F, van Kaick G. Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation. Nucl Med Biol. 1996;23(6):845–9.View ArticleGoogle Scholar
  35. Hollinger EF, Alibazoglu H, Ali A, Green A, Lamonica G. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1998;23(2):93–8.View ArticleGoogle Scholar
  36. Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T, Carr R. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122(1):61–7.View ArticleGoogle Scholar
  37. Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RA, de Klerk JM. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance. Eur J Haematol. 2015;95(1):83–9.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement